急性护理生物标志物能改变脓毒症患者的管理吗?

IF 0.3 Q4 EMERGENCY MEDICINE
S. Di Somma, Luca Crisanti
{"title":"急性护理生物标志物能改变脓毒症患者的管理吗?","authors":"S. Di Somma, Luca Crisanti","doi":"10.4274/eajem.galenos.2022.21.2.1","DOIUrl":null,"url":null,"abstract":"Sepsis and septic shock have an enormous burden on healthcare systems, having more than 30 million people worldwide suffering from those diseases. As emergency providers we must be able to immediately recognize the presence of sepsis to improve the management of this disease and reduce its burden on patient’s lives and on the emergency departments. Biomarkers can play an important role in this attempt. Laboratory tests could help both to identify the presence of sepsis at patients’ arrival and to stratify the risk of progression to septic shock. A new biomarker in that regard is represented by Bioactive Adrenomedullin (BioADM), which mirrors vascular integrity, and is able to detect the physio pathological deterioration of the patients with sepsis that will progress into septic shock. Now, thanks to point-of-care testing devices, we are able to measure BioADM in whole blood in less than twenty minutes, which will help the physician making faster and more adequate therapeutical decisions beside patient’s bed. The good news is that BioADM will also serve as a target for a monoclonal antibody that will counteract the vascular disfunction in septic shock. In conclusion, coupling BioADM with other biomarkers already routinely used such as procalcitonin and lactate we can immediately change patient’s management in Sepsis improving our decision making and patient outcome","PeriodicalId":11814,"journal":{"name":"Eurasian Journal of Emergency Medicine","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Can Acute Care Biomarkers Change Patient’s Management in Sepsis?\",\"authors\":\"S. Di Somma, Luca Crisanti\",\"doi\":\"10.4274/eajem.galenos.2022.21.2.1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Sepsis and septic shock have an enormous burden on healthcare systems, having more than 30 million people worldwide suffering from those diseases. As emergency providers we must be able to immediately recognize the presence of sepsis to improve the management of this disease and reduce its burden on patient’s lives and on the emergency departments. Biomarkers can play an important role in this attempt. Laboratory tests could help both to identify the presence of sepsis at patients’ arrival and to stratify the risk of progression to septic shock. A new biomarker in that regard is represented by Bioactive Adrenomedullin (BioADM), which mirrors vascular integrity, and is able to detect the physio pathological deterioration of the patients with sepsis that will progress into septic shock. Now, thanks to point-of-care testing devices, we are able to measure BioADM in whole blood in less than twenty minutes, which will help the physician making faster and more adequate therapeutical decisions beside patient’s bed. The good news is that BioADM will also serve as a target for a monoclonal antibody that will counteract the vascular disfunction in septic shock. In conclusion, coupling BioADM with other biomarkers already routinely used such as procalcitonin and lactate we can immediately change patient’s management in Sepsis improving our decision making and patient outcome\",\"PeriodicalId\":11814,\"journal\":{\"name\":\"Eurasian Journal of Emergency Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2022-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Eurasian Journal of Emergency Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4274/eajem.galenos.2022.21.2.1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"EMERGENCY MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eurasian Journal of Emergency Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/eajem.galenos.2022.21.2.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"EMERGENCY MEDICINE","Score":null,"Total":0}
引用次数: 0

摘要

败血症和感染性休克给医疗系统带来了巨大负担,全世界有3000多万人患有这些疾病。作为急救人员,我们必须能够立即认识到败血症的存在,以改善对这种疾病的管理,减轻其对患者生活和急诊部门的负担。生物标志物可以在这一尝试中发挥重要作用。实验室测试可以帮助确定患者到达时是否存在败血症,并对进展为败血症休克的风险进行分层。在这方面,一种新的生物标志物以生物活性肾上腺髓质素(BioADM)为代表,它反映了血管的完整性,能够检测败血症患者的生理病理恶化,从而发展为败血症休克。现在,多亏了护理点检测设备,我们能够在不到20分钟的时间内测量全血中的BioADM,这将帮助医生在患者床边做出更快、更充分的治疗决定。好消息是,BioADM还将作为单克隆抗体的靶点,该抗体将对抗感染性休克中的血管功能障碍。总之,将BioADM与其他常规使用的生物标志物(如降钙素原和乳酸)结合,我们可以立即改变脓毒症患者的管理,改善我们的决策和患者的预后
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Can Acute Care Biomarkers Change Patient’s Management in Sepsis?
Sepsis and septic shock have an enormous burden on healthcare systems, having more than 30 million people worldwide suffering from those diseases. As emergency providers we must be able to immediately recognize the presence of sepsis to improve the management of this disease and reduce its burden on patient’s lives and on the emergency departments. Biomarkers can play an important role in this attempt. Laboratory tests could help both to identify the presence of sepsis at patients’ arrival and to stratify the risk of progression to septic shock. A new biomarker in that regard is represented by Bioactive Adrenomedullin (BioADM), which mirrors vascular integrity, and is able to detect the physio pathological deterioration of the patients with sepsis that will progress into septic shock. Now, thanks to point-of-care testing devices, we are able to measure BioADM in whole blood in less than twenty minutes, which will help the physician making faster and more adequate therapeutical decisions beside patient’s bed. The good news is that BioADM will also serve as a target for a monoclonal antibody that will counteract the vascular disfunction in septic shock. In conclusion, coupling BioADM with other biomarkers already routinely used such as procalcitonin and lactate we can immediately change patient’s management in Sepsis improving our decision making and patient outcome
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
50.00%
发文量
39
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信